GLP-1 Medications and Breastfeeding: What Current Research Says About Safety

In the past few years, GLP-1 medications have become some of the most talked-about prescription drugs for weight management and diabetes care. Medications such as Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Saxenda are increasingly being discussed in postpartum spaces as parents navigate weight changes, insulin resistance, PCOS, and metabolic health after pregnancy.

At the same time, many breastfeeding parents are asking an important question: are GLP-1 medications safe while breastfeeding?

The answer is not completely straightforward. Research is still emerging, and while early findings are encouraging for some medications, experts continue to recommend individualized decision-making with a healthcare provider. Here is what current evidence tells us so far.

What Are GLP-1 Medications?

GLP-1 receptor agonists are medications that mimic hormones naturally produced in the body that help regulate blood sugar, appetite, digestion, and feelings of fullness. Some medications in this category are approved for type 2 diabetes, while others are approved specifically for chronic weight management.

Common medications include:

• Semaglutide medications such as Ozempic and Wegovy

• Tirzepatide medications such as Mounjaro and Zepbound

• Liraglutide medications such as Saxenda and Victoza

• Oral semaglutide such as Rybelsus

These medications can be highly effective for blood sugar management and weight loss, which is why postpartum interest has grown significantly in recent years. (JAMA Network)

Why Breastfeeding Safety Questions Exist

Most medications used during lactation are not studied extensively in breastfeeding parents before approval. GLP-1 medications are no exception. For a long time, there was little to no human lactation data available, leading many providers to recommend avoiding these medications while nursing out of caution rather than confirmed evidence of harm.

The primary concerns have included:

• Whether the medication passes into breast milk

• Whether a breastfed infant could absorb the medication

• Possible effects on infant growth or digestion

• Whether rapid maternal weight loss could impact milk supply

• Limited long-term infant outcome data

Recent studies have finally begun to provide more information.

What Research Says About Semaglutide During Breastfeeding

Semaglutide is the active ingredient in Ozempic and Wegovy.

Recent human milk studies found that injectable semaglutide was not detectable in breast milk samples from mothers taking the medication. Researchers also reported no adverse effects in the infants being breastfed during the study period. (Drugs.com)

According to the updated LactMed database, the estimated infant exposure appears extremely low, and semaglutide itself is poorly absorbed orally, meaning that even if trace amounts were present in milk, an infant would likely absorb very little from the digestive tract. (NCBI)

However, an important distinction exists between injectable and oral semaglutide. LactMed specifically notes that oral semaglutide products such as Rybelsus contain an absorption enhancer that may enter breast milk and potentially accumulate in infants. Because of this, injectable forms are generally considered preferable if semaglutide is used during lactation. (Drugs.com)

What Research Says About Tirzepatide During Breastfeeding

Tirzepatide is the active ingredient in Mounjaro and Zepbound.

Emerging data is also encouraging here. A recent lactation study found tirzepatide levels were undetectable in the majority of breast milk samples tested. In the few samples where the medication was measurable, the amount transferred into milk was estimated to be less than 0.02% of the maternal dose. (Drugs.com)

Researchers additionally noted that tirzepatide is a large peptide molecule that would likely be broken down in the infant gastrointestinal tract and poorly absorbed orally. No adverse infant effects were reported in the small number of breastfeeding mothers included in available studies. (Drugs.com)

Still, experts continue to advise caution because long-term infant safety data remains limited, especially for newborns and premature infants. (Drugs.com)

What About Other GLP-1 Medications?

For medications such as Saxenda and Victoza, human breastfeeding data remains far more limited. Much of the available information comes from animal studies or theoretical risk assessment rather than direct milk testing in humans.

Because these medications are also large peptide molecules, many experts suspect milk transfer and infant absorption may be low. However, without stronger lactation data, providers often approach these medications more cautiously.

Could GLP-1 Medications Affect Milk Supply?

This is an area where formal research is still lacking.

Some lactation professionals express concern that significant calorie restriction, dehydration, nausea, or rapid weight loss associated with GLP-1 medications could potentially affect milk production in some breastfeeding parents. Others note that improving insulin resistance and metabolic health may support overall postpartum wellness.

At this time, there is no strong evidence showing that GLP-1 medications directly decrease milk supply, but individual experiences may vary. Parents using these medications while breastfeeding should pay close attention to:

• Hydration

• Adequate calorie intake

• Infant weight gain

• Diaper output

• Milk production changes

Working closely with both a prescribing provider and an IBCLC can help monitor these factors safely.

Current Expert Guidance

Most official prescribing information still uses cautious language because long-term lactation studies remain limited. Many medication labels state that it is unknown whether the medication enters human milk or affects breastfeeding infants. (Baddie Health)

At the same time, newer evidence from LactMed and emerging human milk studies is beginning to shift conversations toward more individualized risk-benefit discussions rather than automatic discontinuation of breastfeeding. (NCBI)

Factors providers may consider include:

• The age of the breastfed infant

• Whether the infant was premature or medically fragile

• Maternal diabetes or metabolic health conditions

• Severity of postpartum obesity or insulin resistance

• Milk supply stability

• Alternative treatment options

For some families, the benefits of maternal treatment may outweigh the theoretical risks.

The Bottom Line

Research on GLP-1 medications during breastfeeding is evolving quickly. Early evidence on semaglutide and tirzepatide suggests that transfer into breast milk may be extremely low or even undetectable in many cases. So far, reported infant effects in small studies have been reassuring. (Drugs.com)

However, long-term safety data is still limited, especially for newborns and exclusively breastfed infants. Because of this, decisions about using medications like Ozempic, Wegovy, Mounjaro, or Zepbound while breastfeeding should always involve individualized conversations with a trusted healthcare provider familiar with both lactation and metabolic health.

As more studies emerge, recommendations may continue to evolve. For now, the growing body of evidence offers cautious optimism while reinforcing the importance of personalized care and informed decision-making for breastfeeding families.